BCN Biosciences is a preclinical biotechnology corporation with core competency in the oncology drug discovery and development market. Our mission is to improve cancer treatment and diagnosis by advancing new therapeutics. BCN Biosciences employs its leading talent for the development and commercialization of small molecule therapeutic candidates. BCN possesses an experienced team of drug discovery and oncology experts coupled with a commitment to developing novel and effective medicines to prevent and treat cancer, one of world's most serious diseases.
Concurrently BCN is developing drugs which target tumors driven by mutations in the RAS protein. KRAS+ cancers represent over 20% of all cancers and significant % of epithelial cancers. These cancers are hard to treat because mutations in RAS make make cancer cells more resistant to to chemotherapeutic drugs as well as cancer immunotherapies. This is most prominent in the specific KRAS mutations of G12C, G12D, G12V and G13D. Such mutations cover a significant population for epithelial cancers such as Colorectal (~40%), Pancreatic (~80%), Head & Neck (~50%), as well as Lung (~35%) and Breast cancer. BCN is developing drugs which target the oncogenic RAS pathway by restoring PTEN expression which is an entirely new mechanism to target. The advantage of this is that the inhibitor is less prone to drug resistance. Recent successes in developing inhibitors against the G12C mutations in KRAS have renewed the excitement in targeting the pathway, however inhibition of the much greater number or G12V and G12D mutations has only advanced beyond preclinical recently. BCN is targeting its assets towards this G12V and G12D mutations which are most predominant in epithelial cancers.
BCN has also a new program in PD-1 regulation which includes small molecule inhibitors of T-cell PD-1 expression in the tumor microenvironment. This differs significantly from the one model in the industry of only blocking the interaction of PD-1 and PD-L1.
Concurrently BCN is developing drugs which target tumors driven by mutations in the RAS protein. KRAS+ cancers represent over 20% of all cancers and significant % of epithelial cancers. These cancers are hard to treat because mutations in RAS make make cancer cells more resistant to to chemotherapeutic drugs as well as cancer immunotherapies. This is most prominent in the specific KRAS mutations of G12C, G12D, G12V and G13D. Such mutations cover a significant population for epithelial cancers such as Colorectal (~40%), Pancreatic (~80%), Head & Neck (~50%), as well as Lung (~35%) and Breast cancer. BCN is developing drugs which target the oncogenic RAS pathway by restoring PTEN expression which is an entirely new mechanism to target. The advantage of this is that the inhibitor is less prone to drug resistance. Recent successes in developing inhibitors against the G12C mutations in KRAS have renewed the excitement in targeting the pathway, however inhibition of the much greater number or G12V and G12D mutations has only advanced beyond preclinical recently. BCN is targeting its assets towards this G12V and G12D mutations which are most predominant in epithelial cancers.
BCN has also a new program in PD-1 regulation which includes small molecule inhibitors of T-cell PD-1 expression in the tumor microenvironment. This differs significantly from the one model in the industry of only blocking the interaction of PD-1 and PD-L1.
BCN Biosciences featured as a technology innovator in Innovate Pasadena.